Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoxetine + lovastatin is a combination of two small molecule drugs, fluoxetine (a selective serotonin reuptake inhibitor antidepressant) and lovastatin (an HMG-CoA reductase inhibitor statin). This combination has been studied for its potential to enhance the treatment of major depressive disorder (MDD), with evidence suggesting that adding lovastatin to fluoxetine may improve depressive symptoms more than fluoxetine alone. Fluoxetine works by inhibiting the reuptake of serotonin in the brain, increasing its availability and thereby improving mood. Lovastatin lowers cholesterol by inhibiting HMG-CoA reductase but may also have anti-inflammatory and neuroprotective effects that could contribute to improved depression outcomes when used adjunctively with SSRIs[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoxetine + lovastatin.